REPLY: Shareholders’ Meeting approves the 2020 Financial Statements
26.4.2021 15:07:00 EEST | Business Wire | Press release
The General Shareholders’ meeting of Reply S.p.A. [MTA, STAR: REY] today approved the Financial Statements for the financial year 2020, confirming the distribution of a gross dividend of €0.56 per share.
The dividend will be paid on 5 May 2021, with dividend date set on 3 May 2021 (record date on 4 May 2021).
2020 Financial Statement
The Reply Group closed the 2020 financial year with a consolidated turnover of €1,250.2 million, recording a 5.7% increase compared to €1,182.5 million for the 2019 financial year.
Consolidated EBITDA was €207.9 million, up 8.7% compared to €191.3 million in 2019.
Consolidated EBIT, from January to December, was €169.5 million, up 9.1% compared to €155.3 million at December 2019.
The Group net profit was at €123.6 million, up 8.6% compared to €113.9 million recorded in 2019.
The Shareholders’ Meeting also approved the following resolutions, in accordance with the proposal of the Board of Directors:
Appointment of the Board of Directors and the Board of Statutory Auditors for the three-year period 2021-2023
The Shareholders’ Meeting appointed the new members to the Board of Directors and the Board of Statutory Auditors for the three-year period 2021-2023 based on the submitted list of candidates.
The following have been appointed as Directors:
- Mario Rizzante (Chairman), Tatiana Rizzante, Filippo Rizzante, Daniele Angelucci, Marco Cusinato, Elena Previtera and Patrizia Polliotto (who declared to comply with the independence requirements set forth in article 148 of the TUF [Testo unico sulla finanza – Financial Act] and the Corporate Governance Code), drawn from the majority list submitted by the shareholder Alika S.r.l. (holder of a 39.754% stake in Reply S.p.A.'s share capital), and obtained the highest number of votes (76.709% of votes obtained);
- Secondina Giulia Ravera and Francesco Umile Chiappetta, who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the minority list submitted by a group of investors (holding a total stake of 3.503% of Reply S.p.A.'s share capital).
The appointed Board of Statutory Auditors consists of three standing members and two alternates:
- Ciro Di Carluccio (Chairman) and Giancarla Branda (Alternate Auditor), who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the minority list submitted by a group of investors (holding a total stake of 3.503% of Reply S.p.A.'s share capital);
- Piergiorgio Re (Standing Auditor), Ada Garzino Demo (Standing Auditor), Stefano Barletta (Alternate Auditor), who declared to comply with the independence requirements set forth in article 148 of the TUF and the Corporate Governance Code, drawn from the majority list submitted by the shareholder Alika S.r.l. (holder of a 39.754% stake in Reply S.p.A.'s share capital), and obtained the highest number of votes (75.741% of votes obtained).
- The curricula vitae of the Directors and Statutory Auditors, as well as the additional documentation required by current legislation, are available in the investors’ section of the company website www.reply.com
Approval of the Programme for the Acquisition and/or Disposal of Own Shares
The Shareholders’ Meeting authorised a new share buyback programme, while withdrawing the current one approved at the Shareholders’ Meeting of 21 April 2020: the main objective of this programme is the purchase of shares to implement the stock incentive plans, transactions aimed at the acquisition of equity investments, extraordinary financial transactions and/or the conclusion of agreements with strategic partners.
The authorization has a duration of 18 months from the date of the resolution, for a maximum of 7,411,457 ordinary shares (equal to 19.8107% of the current share capital) with a nominal value of €0.13 each for a maximum nominal value of €963,489.41, within the limit of a maximum financial commitment of €300,000,000. The purchase price may not be lower than the nominal value (currently €0.13) and higher than the official trading price recorded on the MTA market on the day before the purchase, increased by 20%.
Approval of the Remuneration Report
The Shareholders' Meeting also approved Section II of the Remuneration Report drafted pursuant to Article 123-ter of Legislative Decree 58/1998.
Approval of the delegation of powers to the Board of Directors to increase the share capital with a share premium, subject to withdrawal of the previous delegation of powers granted on 21 April 2016
The Shareholders' Meeting withdrew the mandate conferred to the Board of Directors to increase the share capital, which expired on April 21, 2021, and reauthorized the Board of Directors, in compliance to article 2443 of the Italian Civil Code, to increase the share capital with a share premium and the exclusion of shareholders' option rights in compliance to article 2441, paragraph 4, up to a maximum nominal amount of 390,000.00 Euros through the issue of a maximum of 3,000,000 new Reply S.p.A. ordinary shares with a nominal value of 0.13 Euros each, to be executed in one or more tranches, therefore in a divisible manner, for a maximum period of five years, to be paid through contributions in kind of shares in other companies, having a similar or analogous purpose to the company's or in any case functional to the development of the business. The Shareholders' Meeting consequently resolved to amend Article 5 (Share Capital) of the Articles of Association
The manager in charge of drafting the company's financial reports, Dr Giuseppe Veneziano, declares in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting records.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services www.reply.com
April 26, 2021
This press release is a translation, the Italian version will prevail.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005462/en/
Contact information
Media Contacts
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Investor Relation Contacts
Reply
Riccardo Lodigiani
r.lodigiani@reply.com
Tel. +390117711594
Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
